1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Bipartisan House Support Remains Elusive In 340B Reform Effort

 
• By Cathy Kelly

Republicans continue to take the lead on advancing reforms, while Democrats warn proposals could endanger a government program supporting safety-net care.

Democrats Fear a New House On 340B Bill Goes Too Far. • Source: Shutterstock

The House Energy and Commerce Oversight and Investigations Subcommittee hearing on reforming the 340B outpatient drug discount program showcased the ongoing lack of broad bipartisan agreement on legislation addressing the issue.

Key Takeaways

  • Republicans and Democrats on the committee are not in alignment on how Congress should address possible reforms to the 340B drug discount program.

  • Republicans continue to take the lead on reforms, including transparency requirements for hospitals and defining eligibility for patients who get 340B discounted drugs

Over the past several years, Congress has taken incremental steps toward enhancing oversight of the program and clarifying its scope

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.